Dynamic epstein-barr virus gene expression on the path to B-cell transformation

Advances in Virus Research

Volumn 88, Issue , 2014, Pages 279-313

  Price, Alexander M ^a   Luftig, Micah A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

EBNA; Epstein Barr virus; Herpesvirus; Latency; LMP; Lytic; Viral gene expression; Viral transformation

Indexed keywords

ARTICLE; B LYMPHOCYTE; EBNA; EPSTEIN BARR VIRUS; GENE EXPRESSION REGULATION; HERPES VIRUS; HOST PATHOGEN INTERACTION; HUMAN; LATENT PERIOD; LMP; LYTIC; PATHOGENICITY; PHYSIOLOGY; VIRAL GENE EXPRESSION; VIROLOGY; VIRUS CELL TRANSFORMATION; VIRUS TRANSFORMATION;

EBNA; EPSTEIN-BARR VIRUS; HERPESVIRUS; LATENCY; LMP; LYTIC; VIRAL GENE EXPRESSION; VIRAL TRANSFORMATION;

B-LYMPHOCYTES; CELL TRANSFORMATION, VIRAL; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS;

EID: 84891105292     PISSN: 00653527     EISSN: 15578399     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800098-4.00006-4     Document Type: Chapter

References (159)

1. Adamson A.L., Kenney S. The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase CREB-binding protein. Journal of Virology 1999, 73:6551-6558.
2. Alfieri C., Birkenbach M., Kieff E. Early events in Epstein-Barr virus infection of human B lymphocytes. Virology 1991, 181:595-608.
3. Allday M.J., Crawford D.H., Griffin B.E. Epstein-Barr virus latent gene expression during the initiation of B cell immortalization. Journal of General Virology 1989, 70(Pt 7):1755-1764.
4. Altmann M., Hammerschmidt W. Epstein-Barr virus provides a new paradigm: A requirement for the immediate inhibition of apoptosis. PLoS Biology 2005, 3:e404.
5. Altmann M., Pich D., Ruiss R., Wang J., Sugden B., Hammerschmidt W. Transcriptional activation by EBV nuclear antigen 1 is essential for the expression of EBV's transforming genes. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:14188-14193.
6. Amoroso R., Fitzsimmons L., Thomas W.A., Kelly G.L., Rowe M., Bell A.I. Quantitative studies of Epstein-Barr virus-encoded microRNAs provide novel insights into their regulation. Journal of Virology 2011, 85:996-1010.
7. Arvey A., Tempera I., Tsai K., Chen H.S., Tikhmyanova N., Klichinsky M., et al. An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions. Cell Host & Microbe 2012, 12:233-245.
8. Austin P.J., Flemington E., Yandava C.N., Strominger J.L., Speck S.H. Complex transcription of the Epstein-Barr virus BamHI fragment H rightward open reading frame 1 (BHRF1) in latently and lytically infected B lymphocytes. Proceedings of the National Academy of Sciences of the United States of America 1988, 85:3678-3682.
9. Babcock G.J., Decker L.L., Volk M., Thorley-Lawson D.A. EBV persistence in memory B cells in vivo. Immunity 1998, 9:395-404.
10. Bartel D.P. MicroRNAs: Target recognition and regulatory functions. Cell 2009, 136:215-233.
11. Barth S., Pfuhl T., Mamiani A., Ehses C., Roemer K., Kremmer E., et al. Epstein-Barr virus-encoded microRNA miR-BART2 down-regulates the viral DNA polymerase BALF5. Nucleic Acids Research 2008, 36:666-675.
12. Bechtel J., Grundhoff A., Ganem D. RNAs in the virion of Kaposi's sarcoma-associated herpesvirus. Journal of Virology 2005, 79:10138-10146.
13. Bell A., Skinner J., Kirby H., Rickinson A. Characterisation of regulatory sequences at the Epstein-Barr virus BamHI W promoter. Virology 1998, 252:149-161.
14. Bergbauer M., Kalla M., Schmeinck A., Gobel C., Rothbauer U., Eck S., et al. CpG-methylation regulates a class of Epstein-Barr virus promoters. PLoS Pathogens 2010, 6:e1001114.
15. Booy F.P., Newcomb W.W., Trus B.L., Brown J.C., Baker T.S., Steven A.C. Liquid-crystalline, phage-like packing of encapsidated DNA in herpes simplex virus. Cell 1991, 64:1007-1015.
16. Boya P., Pauleau A.L., Poncet D., Gonzalez-Polo R.A., Zamzami N., Kroemer G. Viral proteins targeting mitochondria: Controlling cell death. Biochimica et Biophysica Acta 2004, 1659:178-189.
17. Bresnahan W.A., Shenk T. A subset of viral transcripts packaged within human cytomegalovirus particles. Science 2000, 288:2373-2376.
18. Cahir-McFarland E.D., Carter K., Rosenwald A., Giltnane J.M., Henrickson S.E., Staudt L.M., et al. Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. Journal of Virology 2004, 78:4108-4119.
19. Cahir-McFarland E.D., Davidson D.M., Schauer S.L., Duong J., Kieff E. NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:6055-6060.
20. Cai X., Schafer A., Lu S., Bilello J.P., Desrosiers R.C., Edwards R., et al. Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathogens 2006, 2:e23.
21. Caldwell R.G., Wilson J.B., Anderson S.J., Longnecker R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 1998, 9:405-411.
22. Choy E.Y., Siu K.L., Kok K.H., Lung R.W., Tsang C.M., To K.F., et al. An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. The Journal of Experimental Medicine 2008, 205:2551-2560.
23. Choy E., Yelensky R., Bonakdar S., Plenge R.M., Saxena R., De Jager P.L., et al. Genetic analysis of human traits in vitro: Drug response and gene expression in lymphoblastoid cell lines. PLoS Genetics 2008, 4:e1000287.
24. Cliffe A.R., Nash A.A., Dutia B.M. Selective uptake of small RNA molecules in the virion of murine gammaherpesvirus 68. Journal of Virology 2009, 83:2321-2326.
25. Cooper A., Johannsen E., Maruo S., Cahir-McFarland E., Illanes D., Davidson D., et al. EBNA3A association with RBP-Jkappa down-regulates c-myc and Epstein-Barr virus-transformed lymphoblast growth. Journal of Virology 2003, 77:999-1010.
26. Cosmopoulos K., Pegtel M., Hawkins J., Moffett H., Novina C., Middeldorp J., et al. Comprehensive profiling of Epstein-Barr virus microRNAs in nasopharyngeal carcinoma. Journal of Virology 2009, 83:2357-2367.
27. Cullen B.R. Herpesvirus microRNAs: Phenotypes and functions. Current Opinion in Virology 2011, 1:211-215.
28. Cullen B.R. Viruses and microRNAs: RISCy interactions with serious consequences. Genes & Development 2011, 25:1881-1894.
29. Demetriades C., Mosialos G. The LMP1 promoter can be transactivated directly by NF-kappaB. Journal of Virology 2009, 83:5269-5277.
30. Dölken L., Malterer G., Erhard F., Kothe S., Friedel C.C., Suffert G., et al. Systematic analysis of viral and cellular microRNA targets in cells latently infected with human gamma-herpesviruses by RISC immunoprecipitation assay. Cell Host & Microbe 2010, 7:324-334.
31. Edwards R.H., Marquitz A.R., Raab-Traub N. Epstein-Barr virus BART microRNAs are produced from a large intron prior to splicing. Journal of Virology 2008, 82:9094-9106.
32. Farrell P.J., Rowe D.T., Rooney C.M., Kouzarides T. Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO Journal 1989, 8:127-132.
33. Faumont N., Durand-Panteix S., Schlee M., Gromminger S., Schuhmacher M., Holzel M., et al. c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells. Journal of Virology 2009, 83:5014-5027.
34. Feederle R., Kost M., Baumann M., Janz A., Drouet E., Hammerschmidt W., et al. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO Journal 2000, 19:3080-3089.
35. Feederle R., Linnstaedt S.D., Bannert H., Lips H., Bencun M., Cullen B.R., et al. A viral microRNA cluster strongly potentiates the transforming properties of a human herpesvirus. PLoS Pathogens 2011, 7:e1001294.
36. Forte E., Luftig M.A. The role of microRNAs in Epstein-Barr virus latency and lytic reactivation. Microbes and Infection 2011, 13:1156-1167.
37. Forte E., Salinas R.E., Chang C., Zhou T., Linnstaedt S.D., Gottwein E., et al. The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells. Journal of Virology 2012, 86:6889-6898.
38. Gires O., Zimber-Strobl U., Gonnella R., Ueffing M., Marschall G., Zeidler R., et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO Journal 1997, 16:6131-6140.
39. Greijer A.E., Dekkers C.A., Middeldorp J.M. Human cytomegalovirus virions differentially incorporate viral and host cell RNA during the assembly process. Journal of Virology 2000, 74:9078-9082.
40. Grossman S.R., Johannsen E., Tong X., Yalamanchili R., Kieff E. The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:7568-7572.
41. Grundhoff A., Sullivan C.S., Ganem D. A combined computational and microarray-based approach identifies novel microRNAs encoded by human gamma-herpesviruses. RNA 2006, 12:733-750.
42. Halder S., Murakami M., Verma S.C., Kumar P., Yi F., Robertson E.S. Early events associated with infection of Epstein-Barr virus infection of primary B-cells. PLoS One 2009, 4:e7214.
43. Henkel T., Ling P.D., Hayward S.D., Peterson M.G. Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. Science 1994, 265:92-95.
44. Henle W., Diehl V., Kohn G., Zur Hausen H., Henle G. Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science 1967, 157:1064-1065.
45. Hickabottom M., Parker G.A., Freemont P., Crook T., Allday M.J. Two nonconsensus sites in the Epstein-Barr virus oncoprotein EBNA3A cooperate to bind the co-repressor carboxyl-terminal-binding protein (CtBP). The Journal of Biological Chemistry 2002, 277:47197-47204.
46. Hislop A.D., Ressing M.E., van Leeuwen D., Pudney V.A., Horst D., Koppers-Lalic D., et al. A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. The Journal of Experimental Medicine 2007, 204:1863-1873.
47. Hurley E.A., Thorley-Lawson D.A. B cell activation and the establishment of Epstein-Barr virus latency. Journal of Experimental Medicine 1988, 168:2059-2075.
48. International HapMap 3 Consortium, Altshuler D.M., Gibbs R.A., Peltonen L., Altshuler D.M., Gibbs R.A., et al. Integrating common and rare genetic variation in diverse human populations. Nature 2010, 467:52-58.
49. Jin X.W., Speck S.H. Identification of critical cis elements involved in mediating Epstein-Barr virus nuclear antigen 2-dependent activity of an enhancer located upstream of the viral BamHI C promoter. Journal of Virology 1992, 66:2846-2852.
50. Jochum S., Moosmann A., Lang S., Hammerschmidt W., Zeidler R. The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination. PLoS Pathogens 2012, 8:e1002704.
51. Jochum S., Ruiss R., Moosmann A., Hammerschmidt W., Zeidler R. RNAs in Epstein-Barr virions control early steps of infection. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:E1396-E1404.
52. Johannsen E., Koh E., Mosialos G., Tong X., Kieff E., Grossman S.R. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1. Journal of Virology 1995, 69:253-262.
53. Johansson P., Jansson A., Ruetschi U., Rymo L. Nuclear factor-kappaB binds to the Epstein-Barr Virus LMP1 promoter and upregulates its expression. Journal of Virology 2009, 83:1393-1401.
54. Joseph A.M., Babcock G.J., Thorley-Lawson D.A. Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. Journal of Virology 2000, 74:9964-9971.
55. Kalla M., Schmeinck A., Bergbauer M., Pich D., Hammerschmidt W. AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:850-855.
56. Katsumura K.R., Maruo S., Wu Y., Kanda T., Takada K. Quantitative evaluation of the role of Epstein-Barr virus immediate-early protein BZLF1 in B-cell transformation. Journal of General Virology 2009, 90:2331-2341.
57. Kaye K.M., Izumi K.M., Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:9150-9154.
58. Keller S.A., Schattner E.J., Cesarman E. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 2000, 96:2537-2542.
59. Kelly G.L., Long H.M., Stylianou J., Thomas W.A., Leese A., Bell A.I., et al. An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: The Wp/BHRF1 link. PLoS Pathogens 2009, 5:e1000341.
60. Kieff E., Rickinson A. Epstein-Barr virus and its replication. Fields virology 2006, 2603-2654. Lippincott, Williams, and Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
61. Kieff E., Rickinson A. Epstein-Barr virus and its replication. Fields virology 2007, 2603-2654. D.M. Knipe, P.M. Howley (Eds.).
62. Kim D.N., Chae H.S., Oh S.T., Kang J.H., Park C.H., Park W.S., et al. Expression of viral microRNAs in Epstein-Barr virus-associated gastric carcinoma. Journal of Virology 2007, 81:1033-1036.
63. Kirby H., Rickinson A., Bell A. The activity of the Epstein-Barr virus BamHI W promoter in B cells is dependent on the binding of CREB/ATF factors. Journal of General Virology 2000, 81(Pt 4):1057-1066.
64. Kitagawa N., Goto M., Kurozumi K., Maruo S., Fukayama M., Naoe T., et al. Epstein-Barr virus-encoded poly(A)(-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction. EMBO Journal 2000, 19:6742-6750.
65. Klapproth K., Sander S., Marinkovic D., Baumann B., Wirth T. The IKK2/NF-{kappa}B pathway suppresses MYC-induced lymphomagenesis. Blood 2009, 114:2448-2458.
66. Knight J.S., Lan K., Subramanian C., Robertson E.S. Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines. Journal of Virology 2003, 77:4261-4272.
67. Krauer K.G., Kienzle N., Young D.B., Sculley T.B. Epstein-Barr nuclear antigen-3 and -4 interact with RBP-2N, a major isoform of RBP-J kappa in B lymphocytes. Virology 1996, 226:346-353.
68. Lautscham G., Mayrhofer S., Taylor G., Haigh T., Leese A., Rickinson A., et al. Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway. The Journal of Experimental Medicine 2001, 194:1053-1068.
69. Laux G., Dugrillon F., Eckert C., Adam B., Zimber-Strobl U., Bornkamm G.W. Identification and characterization of an Epstein-Barr virus nuclear antigen 2-responsive cis element in the bidirectional promoter region of latent membrane protein and terminal protein 2 genes. Journal of Virology 1994, 68:6947-6958.
70. Lee J.M., Lee K.H., Farrell C.J., Ling P.D., Kempkes B., Park J.H., et al. EBNA2 is required for protection of latently Epstein-Barr virus-infected B cells against specific apoptotic stimuli. Journal of Virology 2004, 78:12694-12697.
71. Lee J.M., Lee K.H., Weidner M., Osborne B.A., Hayward S.D. Epstein-Barr virus EBNA2 blocks Nur77- mediated apoptosis. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:11878-11883.
72. Lerner M.R., Andrews N.C., Miller G., Steitz J.A. Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus. Proceedings of the National Academy of Sciences of the United States of America 1981, 78:805-809.
73. Lieberman P.M., Berk A.J. The Zta trans-activator protein stabilizes TFIID association with promoter DNA by direct protein-protein interaction. Genes & Development 1991, 5:2441-2454.
74. Lin J., Johannsen E., Robertson E., Kieff E. Epstein-Barr virus nuclear antigen 3C putative repression domain mediates coactivation of the LMP1 promoter with EBNA-2. Journal of Virology 2002, 76:232-242.
75. Lin Z., Xu G., Deng N., Taylor C., Zhu D., Flemington E.K. Quantitative and qualitative RNA-Seq-based evaluation of Epstein-Barr virus transcription in type I latency Burkitt's lymphoma cells. Journal of Virology 2010, 84:13053-13058.
76. Liu Y., Wang X., Lo A.K., Wong Y.C., Cheung A.L., Tsao S.W. Latent membrane protein-1 of Epstein-Barr virus inhibits cell growth and induces sensitivity to cisplatin in nasopharyngeal carcinoma cells. Journal of Medical Virology 2002, 66:63-69.
77. Lo A.K., To K.F., Lo K.W., Lung R.W., Hui J.W., Liao G., et al. Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:16164-16169.
78. Longnecker R., Druker B., Roberts T.M., Kieff E. An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase. Journal of Virology 1991, 65:3681-3692.
79. Longnecker R., Miller C.L., Miao X.Q., Marchini A., Kieff E. The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential. Journal of Virology 1992, 66:6461-6469.
80. Longnecker R., Miller C.L., Miao X.Q., Tomkinson B., Kieff E. The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro. Journal of Virology 1993, 67:2006-2013.
81. Lu J.J., Chen J.Y., Hsu T.Y., Yu W.C., Su I.J., Yang C.S. Induction of apoptosis in epithelial cells by Epstein-Barr virus latent membrane protein 1. Journal of General Virology 1996, 77(Pt 8):1883-1892.
82. Luftig M., Prinarakis E., Yasui T., Tsichritzis T., Cahir-McFarland E., Inoue J., et al. Epstein-Barr virus latent membrane protein 1 activation of NF-kappaB through IRAK1 and TRAF6. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:15595-15600.
83. Luftig M., Yasui T., Soni V., Kang M.S., Jacobson N., Cahir-McFarland E., et al. Epstein-Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK/IKK alpha-dependent noncanonical NF-kappaB activation. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:141-146.
84. Lung R.W., Tong J.H., Sung Y.M., Leung P.S., Ng D.C., Chau S.L., et al. Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22. Neoplasia 2009, 11:1174-1184.
85. Ma S.D., Hegde S., Young K.H., Sullivan R., Rajesh D., Zhou Y., et al. A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. Journal of Virology 2011, 85:165-177.
86. Ma S.D., Yu X., Mertz J.E., Gumperz J.E., Reinheim E., Zhou Y., et al. An Epstein-Barr virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model. Journal of Virology 2012, 86:7976-7987.
87. Marcinowski L., Lidschreiber M., Windhager L., Rieder M., Bosse J.B., Radle B., et al. Real-time transcriptional profiling of cellular and viral gene expression during lytic cytomegalovirus infection. PLoS Pathogens 2012, 8:e1002908.
88. Marshall D., Sample C. Epstein-Barr virus nuclear antigen 3C is a transcriptional regulator. Journal of Virology 1995, 69:3624-3630.
89. Maruo S., Zhao B., Johannsen E., Kieff E., Zou J., Takada K. Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:1919-1924.
90. Merlo A., Turrini R., Dolcetti R., Martorelli D., Muraro E., Comoli P., et al. The interplay between Epstein-Barr virus and the immune system: A rationale for adoptive cell therapy of EBV-related disorders. Haematologica 2010, 95:1769-1777.
91. Miller C.L., Burkhardt A.L., Lee J.H., Stealey B., Longnecker R., Bolen J.B., et al. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 1995, 2:155-166.
92. Miyazaki I., Cheung R.K., Dosch H.M. Viral interleukin 10 is critical for the induction of B cell growth transformation by Epstein-Barr virus. The Journal of Experimental Medicine 1993, 178:439-447.
93. Montgomery S.B., Sammeth M., Gutierrez-Arcelus M., Lach R.P., Ingle C., Nisbett J., et al. Transcriptome genetics using second generation sequencing in a Caucasian population. Nature 2010, 464:773-777.
94. Mosialos G., Birkenbach M., Yalamanchili R., VanArsdale T., Ware C., Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995, 80:389-399.
95. Nachmani D., Stern-Ginossar N., Sarid R., Mandelboim O. Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host & Microbe 2009, 5:376-385.
96. Nanbo A., Inoue K., Adachi-Takasawa K., Takada K. Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma. EMBO Journal 2002, 21:954-965.
97. Nikitin P.A., Yan C.M., Forte E., Bocedi A., Tourigny J.P., White R.E., et al. An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells. Cell Host & Microbe 2010, 8:510-522.
98. Ning S., Hahn A.M., Huye L.E., Pagano J.S. Interferon regulatory factor 7 regulates expression of Epstein-Barr virus latent membrane protein 1: A regulatory circuit. Journal of Virology 2003, 77:9359-9368.
99. Paschos K., Parker G.A., Watanatanasup E., White R.E., Allday M.J. BIM promoter directly targeted by EBNA3C in polycomb-mediated repression by EBV. Nucleic Acids Research 2012, 40:7233-7246.
100. Paschos K., Smith P., Anderton E., Middeldorp J.M., White R.E., Allday M.J. Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathogens 2009, 5:e1000492.
101. Pearson G.R., Luka J., Petti L., Sample J., Birkenbach M., Braun D., et al. Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex. Virology 1987, 160:151-161.
102. Pfeffer S., Zavolan M., Grasser F.A., Chien M., Russo J.J., Ju J., et al. Identification of virus-encoded microRNAs. Science 2004, 304:734-736.
103. Pickrell J.K., Marioni J.C., Pai A.A., Degner J.F., Engelhardt B.E., Nkadori E., et al. Understanding mechanisms underlying human gene expression variation with RNA sequencing. Nature 2010, 464:768-772.
104. Portal D., Zhao B., Calderwood M.A., Sommermann T., Johannsen E., Kieff E. EBV nuclear antigen EBNALP dismisses transcription repressors NCoR and RBPJ from enhancers and EBNA2 increases NCoR-deficient RBPJ DNA binding. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:7808-7813.
105. Pratt Z.L., Zhang J., Sugden B. The latent membrane protein 1 (LMP1) oncogene of Epstein-Barr virus can simultaneously induce and inhibit apoptosis in B cells. Journal of Virology 2012, 86:4380-4393.
106. Price A.M., Tourigny J.P., Forte E., Salinas R.E., Dave S.S., Luftig M.A. Analysis of Epstein-Barr virus-regulated host gene expression changes through primary B-cell outgrowth reveals delayed kinetics of latent membrane protein 1-mediated NF-kappaB activation. Journal of Virology 2012, 86:11096-11106.
107. Puglielli M.T., Desai N., Speck S.H. Regulation of EBNA gene transcription in lymphoblastoid cell lines: Characterization of sequences downstream of BCR2 (Cp). Journal of Virology 1997, 71:120-128.
108. Puglielli M.T., Woisetschlaeger M., Speck S.H. oriP is essential for EBNA gene promoter activity in Epstein-Barr virus- immortalized lymphoblastoid cell lines. Journal of Virology 1996, 70:5758-5768.
109. Radkov S.A., Bain M., Farrell P.J., West M., Rowe M., Allday M.J. Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21. Journal of Virology 1997, 71:8552-8562.
110. Radkov S.A., Touitou R., Brehm A., Rowe M., West M., Kouzarides T., et al. Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. Journal of Virology 1999, 73:5688-5697.
111. Reisman D., Sugden B. Trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Molecular and Cellular Biology 1986, 6:3838-3846.
112. Rickinson A., Kieff E. Epstein-Barr virus. Fields virology 2007, 2603-2654. Lippincott, Williams, and Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
113. Robertson E.S., Grossman S., Johannsen E., Miller C., Lin J., Tomkinson B., et al. Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa. Journal of Virology 1995, 69:3108-3116.
114. Rogers R.P., Woisetschlaeger M., Speck S.H. Alternative splicing dictates translational start in Epstein-Barr virus transcripts. EMBO Journal 1990, 9:2273-2277.
115. Rooney C., Howe J.G., Speck S.H., Miller G. Influence of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus. Journal of Virology 1989, 63:1531-1539.
116. Rosa M.D., Gottlieb E., Lerner M.R., Steitz J.A. Striking similarities are exhibited by two small Epstein-Barr virus-encoded ribonucleic acids and the adenovirus-associated ribonucleic acids VAI and VAII. Molecular and Cellular Biology 1981, 1:785-796.
117. Roughan J.E., Thorley-Lawson D.A. The intersection of Epstein-Barr virus with the germinal center. Journal of Virology 2009, 83:3968-3976.
118. Rowe M., Khanna R., Jacob C.A., Argaet V., Kelly A., Powis S., et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: Coordinate up-regulation of peptide transporters and HLA-class I antigen expression. European Journal of Immunology 1995, 25:1374-1384.
119. Rymo L. Identification of transcribed regions of Epstein-Barr virus DNA in Burkitt lymphoma-derived cells. Journal of Virology 1979, 32:8-18.
120. Sarcinella E., Brown M., Tellier R., Petric M., Mazzulli T. Detection of RNA in purified cytomegalovirus virions. Virus Research 2004, 104:129-137.
121. Sciortino M.T., Suzuki M., Taddeo B., Roizman B. RNAs extracted from herpes simplex virus 1 virions: Apparent selectivity of viral but not cellular RNAs packaged in virions. Journal of Virology 2001, 75:8105-8116.
122. Seto E., Moosmann A., Gromminger S., Walz N., Grundhoff A., Hammerschmidt W. Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathogens 2010, 6:e1001063.
123. Sinclair A.J. bZIP proteins of human gammaherpesviruses. Journal of General Virology 2003, 84:1941-1949.
124. Sinclair A.J., Palmero I., Peters G., Farrell P.J. EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO Journal 1994, 13:3321-3328.
125. Sjoblom A., Yang W., Palmqvist L., Jansson A., Rymo L. An ATF/CRE element mediates both EBNA2-dependent and EBNA2-independent activation of the Epstein-Barr virus LMP1 gene promoter. Journal of Virology 1998, 72:1365-1376.
126. Skalska L., White R.E., Franz M., Ruhmann M., Allday M.J. Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathogens 2010, 6:e1000951.
127. Skalsky R.L., Corcoran D.L., Gottwein E., Frank C.L., Kang D., Hafner M., et al. The viral and cellular microRNA targetome in lymphoblastoid cell lines. PLoS Pathogens 2012, 8:e1002484.
128. Skalsky R.L., Cullen B.R. Viruses, microRNAs, and host interactions. Annual Review of Microbiology 2010, 64:123-141.
129. Soni V., Cahir-McFarland E., Kieff E. LMP1 TRAFficking activates growth and survival pathways. Advances in Experimental Medicine and Biology 2007, 597:173-187.
130. Sugden B., Warren N. A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection. Journal of Virology 1989, 63:2644-2649.
131. Sun C.C., Thorley-Lawson D.A. Plasma cell-specific transcription factor XBP-1s binds to and transactivates the Epstein-Barr virus BZLF1 promoter. Journal of Virology 2007, 81:13566-13577.
132. Sung N.S., Kenney S., Gutsch D., Pagano J.S. EBNA-2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus. Journal of Virology 1991, 65:2164-2169.
133. Swaminathan S., Tomkinson B., Kieff E. Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro. Proceedings of the National Academy of Sciences of the United States of America 1991, 88:1546-1550.
134. Tempera I., Klichinsky M., Lieberman P.M. EBV latency types adopt alternative chromatin conformations. PLoS Pathogens 2011, 7:e1002180.
135. Terhune S.S., Schroer J., Shenk T. RNAs are packaged into human cytomegalovirus virions in proportion to their intracellular concentration. Journal of Virology 2004, 78:10390-10398.
136. Thorley-Lawson D.A., Allday M.J. The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nature Reviews. Microbiology 2008, 6:913-924.
137. Tierney R., Kirby H., Nagra J., Rickinson A., Bell A. The Epstein-Barr virus promoter initiating B-cell transformation is activated by RFX proteins and the B-cell-specific activator protein BSAP/Pax5. Journal of Virology 2000, 74:10458-10467.
138. Tomkinson B., Robertson E., Kieff E. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. Journal of Virology 1993, 67:2014-2025.
139. van Gent M., Griffin B.D., Berkhoff E.G., van Leeuwen D., Boer I.G., Buisson M., et al. EBV lytic-phase protein BGLF5 contributes to TLR9 downregulation during productive infection. Journal of Immunology 2011, 186:1694-1702.
140. Wahl A., Linnstaedt S.D., Esoda C., Krisko J.F., Martinez-Torres F., Delecluse H.J., et al. A cluster of virus-encoded microRNAs accelerates acute systemic Epstein-Barr virus infection but does not significantly enhance virus-induced oncogenesis in vivo. Journal of Virology 2013, 87:5437-5446.
141. Wang L., Grossman S.R., Kieff E. Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:430-435.
142. Wen W., Iwakiri D., Yamamoto K., Maruo S., Kanda T., Takada K. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes. Journal of Virology 2007, 81:1037-1042.
143. White R.E., Ramer P.C., Naresh K.N., Meixlsperger S., Pinaud L., Rooney C., et al. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. Journal of Clinical Investigation 2012, 122:1487-1502.
144. Woisetschlaeger M., Jin X.W., Yandava C.N., Furmanski L.A., Strominger J.L., Speck S.H. Role for the Epstein-Barr virus nuclear antigen 2 in viral promoter switching during initial stages of infection. Proceedings of the National Academy of Sciences of the United States of America 1991, 88:3942-3946.
145. Woisetschlaeger M., Strominger J.L., Speck S.H. Mutually exclusive use of viral promoters in Epstein-Barr virus latently infected lymphocytes. Proceedings of the National Academy of Sciences of the United States of America 1989, 86:6498-6502.
146. Woisetschlaeger M., Yandava C.N., Furmanski L.A., Strominger J.L., Speck S.H. Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:1725-1729.
147. Xia T., O'Hara A., Araujo I., Barreto J., Carvalho E., Sapucaia J.B., et al. EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Research 2008, 68:1436-1442.
148. Yajima M., Kanda T., Takada K. Critical role of Epstein-Barr virus (EBV)-encoded RNA in efficient EBV-induced B-lymphocyte growth transformation. Journal of Virology 2005, 79:4298-4307.
149. Yalamanchili R., Tong X., Grossman S., Johannsen E., Mosialos G., Kieff E. Genetic and biochemical evidence that EBNA 2 interaction with a 63-kDa cellular GTG-binding protein is essential for B lymphocyte growth transformation by EBV. Virology 1994, 204:634-641.
150. Yates J.L., Warren N., Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985, 313:812-815.
151. Yoo L.I., Mooney M., Puglielli M.T., Speck S.H. B-cell lines immortalized with an Epstein-Barr virus mutant lacking the Cp EBNA2 enhancer are biased toward utilization of the oriP-proximal EBNA gene promoter Wp1. Journal of Virology 1997, 71:9134-9142.
152. Zeidler R., Eissner G., Meissner P., Uebel S., Tampe R., Lazis S., et al. Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood 1997, 90:2390-2397.
153. Zerby D., Chen C.J., Poon E., Lee D., Shiekhattar R., Lieberman P.M. The amino-terminal C/H1 domain of CREB binding protein mediates zta transcriptional activation of latent Epstein-Barr virus. Molecular and Cellular Biology 1999, 19:1617-1626.
154. Zhang Q., Gutsch D., Kenney S. Functional and physical interaction between p53 and BZLF1: Implications for Epstein-Barr virus latency. Molecular and Cellular Biology 1994, 14:1929-1938.
155. Zhang B., Kracker S., Yasuda T., Casola S., Vanneman M., Homig-Holzel C., et al. Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model. Cell 2012, 148:739-751.
156. Zimber-Strobl U., Strobl L.J. EBNA2 and Notch signalling in Epstein-Barr virus mediated immortalization of B lymphocytes. Seminars in Cancer Biology 2001, 11:423-434.
157. Zimber-Strobl U., Suentzenich K.O., Laux G., Eick D., Cordier M., Calender A., et al. Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene. Journal of Virology 1991, 65:415-423.
158. Zuo J., Quinn L.L., Tamblyn J., Thomas W.A., Feederle R., Delecluse H.J., et al. The Epstein-Barr virus-encoded BILF1 protein modulates immune recognition of endogenously processed antigen by targeting major histocompatibility complex class I molecules trafficking on both the exocytic and endocytic pathways. Journal of Virology 2011, 85:1604-1614.
159. Zuo J., Thomas W., van Leeuwen D., Middeldorp J.M., Wiertz E.J., Ressing M.E., et al. The DNase of gammaherpesviruses impairs recognition by virus-specific CD8+ T cells through an additional host shutoff function. Journal of Virology 2008, 82:2385-2393.